Plasma lipid transfer proteins and cardiovascular disea

Atherosclerosis

228, 230-236

DOI: 10.1016/j.atherosclerosis.2013.01.046

Citation Report

#	Article	IF	Citations
1	Phospholipid transfer protein, an emerging cardiometabolic risk marker: Is it time to intervene?. Atherosclerosis, 2013, 228, 38-41.	0.4	13
2	Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. Clinical Lipidology, 2013, 8, 635-648.	0.4	11
3	Periodontal disease and stroke: a metaâ€analysis of cohort studies. European Journal of Neurology, 2014, 21, 1155.	1.7	140
4	HDL Metabolism and Atheroprotection. Advances in Clinical Chemistry, 2014, 65, 1-41.	1.8	29
5	Phospholipid Transfer Protein Deficiency Decreases the Content of S1P in HDL via the Loss of its Transfer Capability. Lipids, 2014, 49, 183-190.	0.7	29
6	HDL-targeted therapies: progress, failures and future. Nature Reviews Drug Discovery, 2014, 13, 445-464.	21.5	289
7	Phospholipid Transfer Protein Destabilizes Mouse Atherosclerotic Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2537-2544.	1.1	11
8	Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism: Clinical and Experimental, 2014, 63, 727-734.	1.5	33
9	Higher level of plasma bioactive molecule sphingosine 1-phosphate in women is associated with estrogen. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 836-846.	1.2	45
10	Did we abandon probucol too soon?. Current Opinion in Lipidology, 2015, 26, 304-316.	1.2	47
11	Low-Normal Thyroid Function and Novel Cardiometabolic Biomarkers. Nutrients, 2015, 7, 1352-1377.	1.7	39
12	Dialysis Modalities and HDL Composition and Function. Journal of the American Society of Nephrology: JASN, 2015, 26, 2267-2276.	3.0	73
13	Increased large <scp>VLDL</scp> particles confer elevated cholesteryl ester transfer in diabetes. European Journal of Clinical Investigation, 2015, 45, 36-44.	1.7	13
14	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. Circulation, 2015, 132, 433-440.	1.6	27
15	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. Circulation, 2015, 132, 423-432.	1.6	24
16	Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease. Atherosclerosis, 2015, 239, 503-508.	0.4	21
17	PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. Journal of Lipid Research, 2015, 56, 1351-1362.	2.0	15
18	Discovery of High-Density Lipoprotein Gene Targets from Classical Genetics to Genome-Wide Association Studies. , 2016, , 119-159.		2

#	Article	IF	Citations
19	Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1159-1167.	0.9	13
20	Very High Levels of High-Density Lipoprotein Cholesterol and Cardiovascular Events in Japanese Population. Journal of Atherosclerosis and Thrombosis, 2016, 23, 771-772.	0.9	3
21	Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 746-756.	0.9	15
22	Serum CETP and PLTP activity in middle-aged men living in urban or rural area of the Lower Silesia region. PURE Poland sub-study. Archives of Medical Science, 2016, 4, 704-714.	0.4	2
23	HDL functionality in reverse cholesterol transport â€" Challenges in translating data emerging from mouse models to human disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 566-583.	1.2	73
24	CETP Inhibition in CVD Prevention: an Actual Appraisal. Current Cardiology Reports, 2016, 18, 43.	1.3	14
25	The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?. European Journal of Clinical Investigation, 2016, 46, 581-589.	1.7	3
26	Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation. Current Opinion in Lipidology, 2016, 27, 459-472.	1.2	25
27	Postprandial Studies Uncover Differing Effects on HDL Particles of Overt and Subclinical Hypothyroidism. Thyroid, 2016, 26, 356-364.	2.4	14
28	Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport. Journal of Lipid Research, 2017, 58, 731-741.	2.0	13
29	Evacetrapib. Cardiology in Review, 2017, 25, 43-52.	0.6	20
30	Alterations in high-density lipoprotein proteome and function associated with persistent organic pollutants. Environment International, 2017, 98, 204-211.	4.8	19
31	Capsaicin Supplementation Improved Risk Factors of Coronary Heart Disease in Individuals with Low HDL-C Levels. Nutrients, 2017, 9, 1037.	1.7	23
32	Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis. Journal of Lipid Research, 2018, 59, 764-771.	2.0	27
33	Prodomain of Furin Promotes Phospholipid Transfer Protein Proteasomal Degradation in Hepatocytes. Journal of the American Heart Association, 2018, 7, .	1.6	4
34	Plasma Phospholipid Transfer Protein Promotes Platelet Aggregation. Thrombosis and Haemostasis, 2018, 118, 2086-2097.	1.8	10
35	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	1.2	2
36	CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes, 2018, 67, 2494-2506.	0.3	20

#	Article	IF	Citations
37	Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2018, 48, e12988.	1.7	17
38	Alteration of HDL Protein Composition with Hemodialysis Initiation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1225-1233.	2.2	20
39	Association of Serum Cholesterol Ester Transfer Protein Levels with Taq IB Polymorphism in Acute Coronary Syndrome. Laboratory Medicine, 2020, 51, 199-210.	0.8	2
40	Modified lipoproteins in periodontitis: a link to cardiovascular disease?. Bioscience Reports, 2019, 39, .	1.1	21
41	Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency. Journal of Clinical Lipidology, 2019, 13, 317-325.	0.6	20
42	Preî21-high-density lipoprotein metabolism is delayed in patients with chronic kidney disease not on hemodialysis. Journal of Clinical Lipidology, 2020, 14, 730-739.	0.6	5
43	Cholesteryl ester transfer protein inhibitors in precision medicine. Clinica Chimica Acta, 2020, 510, 733-740.	0.5	4
44	Highâ€density lipoproteinâ€related cholesterol metabolism in Alzheimerâ€™s disease. Journal of Neurochemistry, 2021, 159, 343-377.	2.1	8
45	Cholesteryl Ester Transfer Protein Impairs Triglyceride Clearance via Androgen Receptor in Male Mice. Lipids, 2021, 56, 17-29.	0.7	7
46	The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis. Current Atherosclerosis Reports, 2021, 23, 9.	2.0	13
47	Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis. Atherosclerosis, 2021, 324, 9-17.	0.4	8
48	Impact of Phospholipid Transfer Protein in Lipid Metabolism and Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2020, 1276, 1-13.	0.8	3
49	Serum Lipid Transfer Proteins in Hypothyreotic Patients Are Inversely Correlated with Thyroid-Stimulating Hormone (TSH) Levels. Medical Science Monitor, 2016, 22, 4661-4669.	0.5	9
50	CETP inhibitors and cardiovascular disease: Time to think again. F1000Research, 2014, 3, 124.	0.8	16
51	Links between Insulin Resistance, Lipoprotein Metabolism and Amyloidosis in Alzheimerâ€™s Disease. Health, 2014, 06, 1549-1579.	0.1	10
53	Cholesteryl Ester Transfer Protein Inhibitors â€“ Future Soon to be REVEALed. European Cardiology Review, 2015, 10, 64.	0.7	0
54	Taq1B CETP Polymorphism and Cardiovascular Risk in an Endogamous Pop-ulation of Diabetic Men: A Study in Santa Rosa Del Conlara, San Luis, Argentina. Journal of Diabetes Mellitus, 2015, 05, 123-134.	0.1	1
56	Expressing the Human Cholesteryl Ester Transfer Protein Minigene Improves Diet-Induced Fatty Liver and Insulin Resistance in Female Mice. Frontiers in Physiology, 2021, 12, 799096.	1.3	4

#	Article	IF	Citations
58	Alterations of HDLâ€™s to piHDLâ€™s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals, 2022, 15, 1278.	1.7	9
59	Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke. Nature Communications, 2022, 13, .	5.8	25